{
    "nct_id": "NCT05142696",
    "official_title": "A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide, and Atezolizumab in Induction and With Atezolizumab in Maintenance Phase",
    "inclusion_criteria": "* Participant is >= 18 years on the day of signing informed consent form\n* Histologically or cytologically confirmed ES-SCLC\n* Presence of measurable disease (at least one target lesion) according to RECIST v1.1 assessed by conventional computed tomography (CT) scan\n* No prior systemic treatment for ES-SCLC (except the first cycle of chemotherapy with or without atezolizumab of the induction period\n* ECOG status =< 1\n* Provision of tumor tissue to support exploratory biomarker analysis\n* Life expectancy of >= 6 months\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Participant has received prior therapy with an antibody or drug against immune checkpoint pathways\n* Active autoimmune diseases or history of autoimmune diseases that may relapse\n* Severe chronic or active infections (including active tuberculosis, HBV, or HCV infection) requiring systemic antibacterial, antifungal or antiviral therapy within 2 weeks before Cycle 1 Day 1\n* Any major surgical procedure requiring general anesthesia =< 28 days before Cycle 1 Day 1\n* History or current diagnosis of electrocardiogram (ECG) abnormalities indicating significant risk of safety for participants participating in the study\n* Known hypersensitivity to the active substances or any of the excipients of the study drugs\n* Concurrent participation in another therapeutic clinical study",
    "miscellaneous_criteria": "Key"
}